| Autor: |
Schaad, H J, Petty, B G, Grasela, D M, Christofalo, B, Raymond, R, Stewart, M |
| Zdroj: |
Antimicrobial Agents and Chemotherapy; December 1997, Vol. 41 Issue: 12 p2793-2796, 4p |
| Abstrakt: |
This open-label study enrolled five subjects with biopsy-proven cirrhosis and moderate to severe hepatic impairment (Child-Pugh classification grade B or C) and five age- and gender-matched controls. All subjects received a single 40-mg oral dose of stavudine (d4T). Stavudine pharmacokinetics in subjects with hepatic impairment were similar to those in age- and gender-matched control subjects and were not substantially different from those previously observed in human immunodeficiency virus-infected patients. Based on these findings, stavudine use does not require modification of the dose or dosing interval for patients with liver disease. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
